Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients

Diabetes Research and Clinical Practice

Volumn 98, Issue 1, 2012, Pages 68-74

  Domínguez, Raúl O ^a   Marschoff, Enrique R ^a   González, Silvia E ^a   Repetto, Marisa G ^a   Serra, Jorge A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Alzheimer's disease; Cognitive performance; Cognitive tests; Type 2 Diabetes Mellitus

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; SULFONYLUREA;

ADULT; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DETERIORATION; MENTAL PERFORMANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PILOT STUDY;

AGED; ALZHEIMER DISEASE; ARGENTINA; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GERIATRIC ASSESSMENT; HIPPOCAMPUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES;

EID: 84867405121     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.05.013     Document Type: Article

References (43)

1. Ritchie K., Lovestone S. The dementias. Lancet 2002, 360:1759-1766.
2. Biessels G.J., Staekenborg S., Brunner E., Brayne C., Scheltens P.C. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006, 5:64-74.
3. Korf E.S.C., Lon R., White L.R., Scheltens P.H., Lenore J., Launer L.J. Brain aging in very old men with type 2 diabetes. Diabetes Care 2006, 29:2268-2274.
4. Schrijvers E.M., Witteman J.C., Sijbrands E.J., Hofman A., Koudstaal P.J., Breteler M.M. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam study. Neurology 2010, 75(22):1982-1987.
5. Serra J.A., Marschoff E.R., Domínguez R.O., Guareschi E.M., Famulari A.L., Lustig E.S. Oxidative stress in Alzheimer's and vascular dementias: masking of the antioxidant profiles by a concomitant Type II diabetes mellitus condition. J Neurol Sci 2004, 218:17-24.
6. Domínguez R.O., Marschoff E.R., Guareschi E.M., Famulari A.L., Pagano M.A., Serra J.A. Homocysteine, vitamin B12 and folate in Alzheimer's and vascular dementias: the paradoxical effect of the superimposed Type II Diabetes Mellitus condition. Clin Chim Acta 2005, 359:163-170.
7. Domínguez R.O., Marschoff E.R., Guareschi E.M., Repetto M.G., Famulari A.L., Serra J.A. Insulin, glucose and glycated hemoglobin in Alzheimer's and vascular dementia with and without superimposed Type II diabetes mellitus condition. J Neural Transm 2008, 115:77-84.
8. Serra J.A., Domínguez R.O., Marschoff E.R., Guareschi E.M., Famulari A.L., Boveris A. Systemic oxidative stress associated with the neurological diseases of aging. Neurochem Res 2009, 34:2122-2132.
9. Sanz C., Andrieu S., Sinclair A., Hanaire H., Vellas B., REAL FR Study Group Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 2009, 73:1359-1366.
10. Akter K., Lanza E.A., Martin S.A., Myronyuk N., Rua M., Raffa R.B. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. Br J Clin Pharmacol 2011, 71:365-376.
11. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012, 69(1):29-38.
12. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984, 141(11):1356-1364.
13. Schwarb S., Koberle S., Spiegel R. The Alzheimer's Disease Assessment Scale (ADAS): an instrument for early diagnosis of dementia?. Int J Geriatr Psychiatry 1988, 3:45-53.
14. Folstein M.F., Folstein S.E., McHugh P.R. Mini mental state: a practical method for grading the cognitive state of patient for the clinician. J Psychiatr Res 1975, 12:189-198.
15. Hughes C.P., Berg L., Danziger W.L., Coban L.A., Martin R.L. A new clinical scale for the staging of dementia (CDR). Br J Psychiatry 1982, 140:566-572.
16. Mc Khan G., Drachman D., Folstein M., Katzman R., Price C., Stardlan M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force of Alzheimer's Disease. Neurology 1984, 34:939-944.
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000, 23:S4-S19.
18. American Psychiatric Association Diagnostic and statistical manual of mental disorders (DSM IV) 1994, American Psychiatric Association, Washington, USA. 4th ed.
19. Hamilton M.A. Rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
20. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003, 289:2560-2571.
21. Davison A.C., Hinkley D.V. Bootstrap methods and their application 1997, Cambridge University Press, Cambridge, England.
22. Hoyos Flight M. Ageing: rescuing age-related memory loss. Nat Rev Neurosci 2011, 12:490-491.
23. Villeda S.A., Luo J., Mosher K.I., Zou B., Britschgi M., Bieri G., et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011, 477:90-94.
24. Srikanth V., Maczurek A., Phan T., Steele M., Westcott B., Juskiw D., et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011, 32(5):763-777.
25. Sonnen J.A., Larson E.B., Gray S.G., Wilson A., Kohama S.G., Crane P.K., et al. Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury and smoking. Ann Neurol 2009, 65:226-229.
26. Sonnen J.A., Larson E.B., Brickell K., Crane P.K., Woltjer R., Montine T.J., et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009, 66:315-322.
27. Duncan B., Schmidt M., Pankow J., Ballantyne C., Couper D., Vigo A., et al. Low-grade systemic inflammation and the development of Type-II Diabetes. The atherosclerosis risk in communities study. Diabetes 2003, 52:1797-1805.
28. Hernández-Mijares A., Rocha M.C., Apostolova N., Borrás C., Jover A., Bañuls C., et al. Mitochondrial complex I impairment in leukocytes from Type 2 diabetic patients. Free Radic Biol Med 2011, 50:1215-1221.
29. Opazo C., Barría M.I., Ruiz F.H., Inestrosa N.C. Copper reduction by copper binding proteins and its relation to neurodegenerative diseases. Biometals 2003, 16:91-98.
30. Kozlowski H., Janck-Klos A., Brasun J., Gaggelli E., Valensin D., Valensin G. Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation). Coord Chem Rev 2009, 253:2665-2685.
31. Navarro A., Boveris A. Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease. J Bioenerg Biomembr 2009, 41:517-521.
32. Wellen K., Hotamisligil G. Inflammation, stress and diabetes. J Clin Invest 2005, 115:1111-1119.
33. Heilbronn I., Campbell L. Adipose tissue macrophages, low-grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008, 14:1225-1230.
34. Repetto M.G., Domínguez R.O., Marschoff E.R., Serra J.A. Free radicals, oxidative stress and oxidative damage in Parkinson's disease. Mechanisms in Parkinson's disease-models and treatments 2012, 57-78. InTech Publisher, Rijeka, Croatia. J. Dushanova (Ed.).
35. Boveris A., Navarro A. Brain mitochondrial dysfunction in aging. Life 2008, 60(5):308-314.
36. De Giorgio R., Barbara G., Cecconi A., Corinaldesi R., Mancini A.M. Diabetes is associated with longer survival rates in patients with malignant tumors. Arch Intern Med 2001, 161:485.
37. Hanbali A. Diabetes has protective effect against metastasis in patients with non-small cell lung cancer. J Clin Oncol 2004, 22:7234.
38. Hanbali A., Al-Khasawneh K., Cole-Johnson C., Divine G., Ali H. Protective effect of diabetes against metastasis in patients with non-small cell lung cancer. Arch Intern Med 2007, 167:513.
39. De Felice F.G., Vieira M.N.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc Natl Acad Sci U S A 2009, 106(6):1971-1976.
40. Baraka A., ElGhotny S. Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats. Eur J Pharmacol 2010, 64:123-127.
41. Kickstein E., Krauss S., Thornhill P., Rutschow D., Zeller R., Sharkey J., et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 2010, 107:21830-21835.
42. Gupta A., Bisht B., Dey C.S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011, 60:910-920.
43. Emery V.O. Alzheimer disease: are we intervening too late?. J Neural Transm 2011, 118(9):1361-1378.